Similar articles

• Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

  Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Sabatine MS, et al. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773607 Clinical Trial.
• Evolocumab in Patients with Cardiovascular Disease.

  Nunes JPL. Nunes JPL. N Engl J Med. 2017 Aug 24;377(8):787. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834473 No abstract available.
• Evolocumab in Patients with Cardiovascular Disease.

  Sabatine MS, Giugliano RP, Pedersen TR. Sabatine MS, et al. N Engl J Med. 2017 Aug 24;377(8):787-8. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834471 No abstract available.
• Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.

  Henry CA, Lyon RA, Ling H. Henry CA, et al. Vasc Health Risk Manag. 2016 Apr 19;12:163-9. doi: 10.2147/VHRM.S82387. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27143910 Free PMC article. Review.
• Effects of Evolocumab on Cardiovascular Events.

  Mikhail N. Mikhail N. Curr Cardiol Rev. 2017;13(4):319-324. doi: 10.2174/1573403X13666170918165713. Curr Cardiol Rev. 2017. PMID: 28925859 Free PMC article. Review.